Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.
Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.
Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.
By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.
Cerus Corporation (CERS) announced preliminary product revenues for Q4 2021 at
Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Stephens Annual Investment Conference on December 3, 2021, at 2:00 p.m. ET in Nashville, Tennessee. A live webcast will be accessible on the Cerus Investor Relations page, with a replay available for about two weeks post-event. Cerus is focused on safeguarding the global blood supply, offering technologies like the INTERCEPT Blood System, which has CE Mark and FDA approval for pathogen reduction in platelets and plasma. For details, visit www.cerus.com/ir.
On November 15, 2021, Cerus Corporation (CERS) will participate in the Stifel 2021 Virtual Healthcare Conference, featuring CEO William ‘Obi’ Greenman and CFO Kevin D. Green. The event is set for 4:40 p.m. ET, with a live webcast available on Cerus' Investor Relations page. Cerus is focused on ensuring blood safety, developing technologies like the INTERCEPT Blood System, which is approved for pathogen reduction in platelets and plasma. The company aims to lead in global blood products.
Cerus Corporation (CERS) reported strong financial results for Q3 2021, with total revenue of $42.1 million, a 44% increase year-over-year. Product revenue reached $36.1 million, up 53% compared to Q3 2020. The company raised its full-year 2021 product revenue guidance to a range of $127-129 million, anticipating a growth of 38-40% over the previous year. Despite operational expenses increasing to $35.6 million, net loss improved to $12.4 million from last year's $14.1 million. Cerus continues to see significant demand for the INTERCEPT Blood System.
Cerus Corporation (NASDAQ: CERS) will release its third quarter 2021 financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for 4:30 PM ET on the same day, where management will discuss the financial results and provide a business overview. The INTERCEPT Blood System, the company's flagship product, remains the only pathogen reduction system with CE mark and FDA approval for platelets and plasma. A replay of the call will be available post-event until November 16, 2021.
Today, the FDA's final guidance on bacterial risk control for platelet collection and transfusion takes effect, promoting the INTERCEPT Blood System for platelets by Cerus (CERS) as a compliant pathogen reduction solution. This system not only addresses bacterial contamination—recognized as a major risk in the U.S.—but also inactivates a range of viruses and parasites. The guidance aims to enhance platelet safety and availability for transfusions across the U.S., marking a significant milestone in transfusion medicine, as INTERCEPT is currently the only FDA-approved measure for compliance.
Cerus Corporation (NASDAQ: CERS) will participate in the Society for the Advancement of Blood Management Annual Meeting from September 22-25, 2021. On September 23, Cerus will host a workshop discussing the clinical need for the INTERCEPT Fibrinogen Complex, featuring presentations from hospital customers. The INTERCEPT Blood System for Cryoprecipitation is FDA approved since November 2020, aimed at improving treatment of massive hemorrhage. Additionally, CMS has granted a New Technology Add-On Payment for the INTERCEPT Fibrinogen Complex.
Cerus Corporation (Nasdaq: CERS) announces participation in the 2021 Cantor Global Virtual Healthcare Conference on September 29, 2021, at 11:20 a.m. ET. CEO William 'Obi' Greenman and CFO Kevin D. Green will represent the company. A live webcast will be accessible on Cerus’ Investor Relations page, with a replay available for two weeks post-event. Cerus is committed to protecting the global blood supply, offering the INTERCEPT Blood System, which has CE mark and FDA approval for pathogen reduction in platelets and plasma. For further details, visit Cerus Investor Relations.
Cerus Corporation (Nasdaq: CERS) has received permanent HCPCS Level II codes from CMS for its INTERCEPT Fibrinogen Complex (IFC) and Pathogen Reduced Plasma, effective October 1, 2021. These codes will aid hospitals in billing for these innovative products, enhancing access to transfusion medicine. Earlier, Cerus announced a new technology add-on payment for IFC within the Medicare Hospital Inpatient Prospective Payment System. The INTERCEPT Blood System, which also includes IFC, is designed for treating massive hemorrhage and has FDA Breakthrough Device designation.
Cerus Corporation (Nasdaq: CERS) has appointed Ann Lucena, CEO of San Ramon Regional Medical Center, to its Board of Directors. With a strong background in healthcare management, Lucena's experience is expected to add valuable insights from the provider community as Cerus aims to expand its blood safety product portfolio. Daniel Swisher, Chair of the Board, expressed enthusiasm for her addition, highlighting the ongoing paradigm shift in transfusion medicine and the importance of blood safety. Lucena's prior roles include Chief of Staff at Tenet Healthcare and healthcare consulting.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is Cerus Corporation's main focus?
What pathogens does the INTERCEPT Blood System target?
Where is the INTERCEPT Blood System marketed?
What products does Cerus Corporation offer?
What are some recent achievements of Cerus Corporation?
How does the INTERCEPT Blood System work?
What financial strategies does Cerus Corporation employ?
Is Cerus Corporation involved in research for emerging pathogens?
What regions are key markets for Cerus Corporation?
What segment does Cerus Corporation operate in?
